BioBridgeX
Log inCompare quotes
Modality

Other RNA Therapeutics CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Other RNA therapeutics covers the newer RNA classes beyond mRNA and standard oligonucleotides: circular RNA, self-amplifying constructs, RNA aptamers, guide and tRNA-based drugs. Outsourcing it means sourcing CROs and CDMOs for sequence design, chemistry, delivery (often LNP), GMP RNA synthesis, and analytics. On BioBridgeX you compare qualified vendors as the neutral vendor of record, free for buyers, under one contract.

Other RNA Therapeutics CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Other RNA Therapeutics CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture an Other RNA Therapeutics drug?

"Other RNA" is the catch-all bucket for the RNA classes that do not fit the named modalities. mRNA and saRNA have their own lane, antisense and siRNA sit under oligonucleotides, and plasmid DNA is its own category. What is left over is the fast-moving edge: circular RNA, self-amplifying constructs beyond classic saRNA, RNA aptamers, standalone guide RNAs, tRNA-based therapeutics, and the assorted structured RNAs that keep appearing in early pipelines. The biology differs across them, but the development and manufacturing problem rhymes, which is why buyers can source it as one modality even though the molecules are not interchangeable.

Discovery and preclinical work here is mostly sequence and chemistry. You design the construct, screen chemical modifications and caps or end structures for stability and reduced innate-immune triggering, and run the in vitro and in vivo studies that tell you whether the RNA reaches the target tissue and does what you intended. Two questions dominate the early program: does the molecule survive long enough to act, and can you get it inside the right cell. The second question is usually the harder one. Most RNA payloads need a delivery system, lipid nanoparticles most often, sometimes conjugates or other carriers, and the delivery vehicle is frequently the part that decides whether the drug works at all. A CRO that is strong on RNA biology but has never formulated an LNP will leave you with a gap exactly where programs fail.

On the CMC and manufacturing side, RNA is made by in vitro transcription or chemical synthesis rather than fermentation or cell culture, and that changes the vendor you need. The template, the enzymatic reaction, the capping and tailing chemistry, the purification (often chromatography to strip double-stranded RNA and process impurities), the LNP encapsulation step, and the fill-finish all have to run to GMP for clinical material. The analytical package is where a specialist RNA CDMO genuinely separates from a generalist: integrity and length by capillary electrophoresis, identity by sequencing, residual dsRNA and template DNA, capping efficiency where it applies, plus encapsulation efficiency and particle size for the formulated product. A generalist biologics shop can run a lot of this, but the RNA-specific impurities and the delivery analytics are where the experience shows. The named catalog services that map most directly to this work are mRNA/RNA manufacturing and LNP/delivery formulation, and the right vendor usually has both under one roof or a tight handoff between them.

How do you choose a CRO or CDMO for Other RNA Therapeutics?

Because "other RNA" spans several molecule types, fit to your specific construct matters more than a general RNA reputation. A team that has shipped mRNA does not automatically know circular RNA purification or aptamer chemistry. Score two or three vendors against the same written scope, weight platform and delivery experience heavily, and confirm the analytics actually exist for your molecule rather than being adapted on your budget.

  • Relevant platform and track record: ask which RNA classes the team has actually run (circRNA, saRNA, aptamer, guide RNA, tRNA), not just "RNA," and whether they have completed comparable programs end to end. The molecule type drives the chemistry and the purification, so a near-match in modality is worth more than a bigger logo.
  • Delivery capability: most RNA payloads need a carrier, so confirm in-house LNP or conjugate formulation, or a vendor with a tight, proven handoff to a formulation partner. Delivery is where these programs most often stall, and a synthesis-only vendor leaves that risk with you.
  • GxP and analytical capability for this modality: confirm GLP for the safety work and GMP for clinical material, then check the RNA-specific analytics directly: integrity and length, identity by sequencing, residual dsRNA and template DNA, capping efficiency where relevant, and encapsulation efficiency and particle size for the formulated product. Ask which methods are validated versus fit-for-purpose.
  • Capacity and scale: ask the realistic scale they can make today and the path to clinical and beyond, plus current queue. RNA scale-up is non-trivial, and a strong lab booked solid for months can be slower than a good lab with an open slot. Pin a milestone timeline, not just a price.
  • Regulatory experience: RNA guidance is still maturing and varies by region, so favor a partner that has supported an IND or equivalent for an RNA product and knows what the FDA, EMA, or PMDA expect for characterization, impurities, and a novel delivery system. A clean inspection history matters more than the cheapest quote.
  • IP and freedom to operate: settle ownership of constructs, sequences, and any platform-derived improvements before work starts, and clarify rights to a vendor's delivery technology, since LNP and conjugate chemistry are often heavily patented and can constrain your freedom to operate later.

Frequently asked questions

What counts as an "Other RNA Therapeutic" versus mRNA or an oligonucleotide?
It is the bucket for RNA drugs that do not fit the named categories. mRNA and saRNA are their own modality, antisense oligonucleotides and siRNA sit under oligonucleotides, and plasmid DNA is separate. "Other RNA" captures what is left: circular RNA, self-amplifying constructs beyond classic saRNA, RNA aptamers, standalone guide RNAs, tRNA-based therapeutics, and other structured or emerging RNA formats. If your molecule is clearly an mRNA vaccine or a classic siRNA, use those categories. If it is a newer RNA class that does not have its own page yet, this is where it belongs.
Do I need a different CDMO for RNA than for a typical biologic?
Usually yes. RNA is made by in vitro transcription or chemical synthesis, not cell culture or fermentation, so the process, the equipment, and especially the analytics differ from a monoclonal antibody or recombinant protein. The RNA-specific work, capping and tailing chemistry, removing double-stranded RNA and residual template, integrity and length testing, and encapsulating the RNA into an LNP, is where a specialist separates from a generalist. A broad biologics CDMO can run some of it, but for a novel RNA construct and a novel delivery system, experience with the modality is what reduces your risk.
Why does delivery matter so much for RNA, and should the same vendor handle it?
Naked RNA is fragile and does not readily cross the cell membrane, so most RNA drugs need a carrier to reach the target tissue and get inside the cell. Lipid nanoparticles are the most common approach, with conjugates and other systems used in specific cases. Delivery is frequently the part that decides whether the drug works at all, which is why it is worth confirming up front. Having synthesis and LNP formulation under one roof, or a tight, proven handoff between two partners, avoids the gap where the RNA is made well but never reaches its target.
What analytical testing should an RNA CDMO be able to run?
Expect integrity and length analysis (often by capillary electrophoresis), identity confirmation by sequencing, and purity measures that catch RNA-specific impurities such as residual double-stranded RNA and leftover template DNA. Where the construct uses a cap, capping efficiency is part of the release panel. For the formulated product, you also need encapsulation efficiency and particle size on the LNP or other carrier. Ask which of these methods are validated versus fit-for-purpose, because the answer tells you whether the vendor is ready for clinical material or still building the package on your program.
How mature is the regulatory path for newer RNA modalities?
It is still developing and less settled than for small molecules or established biologics. The COVID mRNA vaccines created real precedent and built reviewer familiarity, but newer classes like circular RNA, aptamers, and novel delivery systems carry more open questions on characterization, impurity limits, and the safety of the carrier. Expect to justify your analytical strategy and your delivery system in more detail. A CRO or CDMO that has supported an IND or equivalent for an RNA product, and knows current FDA, EMA, or PMDA thinking, is worth more here than on a well-trodden modality.
How does sourcing an RNA CRO or CDMO through BioBridgeX work?
You describe the work (the RNA class, the delivery approach, the services, the stage, and the indication) and get matched with qualified CRO and CDMO vendors who do that specific work. Vendor profiles are public, so you can size up RNA and delivery experience before any sales call. BioBridgeX is the neutral vendor of record and runs no lab of its own, so there is no incentive to steer you toward a preferred site. It is free for buyers, vendors pay a flat 2% platform fee, and when a program spans several vendors (say synthesis, LNP formulation, and analytics) you sign one contract, raise one PO, and get one invoice across all of them, across every indication and modality.

Source Other RNA Therapeutics work with one contract

Compare transparent quotes from qualified Other RNA Therapeutics CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes